Role of interleukin‑32 in cancer biology (Review)
- Authors:
- Haimeng Yan
- Donghua He
- Xi Huang
- Enfan Zhang
- Qingxiao Chen
- Ruyi Xu
- Xinling Liu
- Fuming Zi
- Zhen Cai
-
Affiliations: Bone Marrow Transplantation Centre, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, P.R. China, Department of Haematology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330001, P.R. China - Published online on: May 7, 2018 https://doi.org/10.3892/ol.2018.8649
- Pages: 41-47
This article is mentioned in:
Abstract
 |
|
Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Colotta F, Allavena P, Sica A, Garlanda C and Mantovani A: Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis. 30:1073–1081. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hanahan D and Weinberg R: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Liu Z, Balivada S, Shrestha T, Bossmann S, Pyle M, Pappan L, Shi J and Troyer D: Interleukin-1β and transforming growth factor-β cooperate to induce neurosphere formation and increase tumorigenicity of adherent LN-229 glioma cells. Stem Cell Res Ther. 3:52012. View Article : Google Scholar : PubMed/NCBI | |
|
Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C and Lin J: STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 71:7226–7237. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Srivastava SK, Bhardwaj A, Arora S, Tyagi N, Singh AP, Carter JE, Scammell JG, Fodstad Ø and Singh S: Interleukin-8 is a key mediator of FKBP51-induced melanoma growth, angiogenesis and metastasis. Br J Cancer. 112:1772–1781. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tao H, Lu L, Xia Y, Dai F, Wang Y, Bao Y, Lundy SK, Ito F, Pan Q, Zhang X, et al: Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10. Eur J Immunol. 45:999–1009. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshimoto T, Chiba Y, Furusawa J, Xu M, Tsunoda R, Higuchi K and Mizoguchi I: Potential clinical application of interleukin-27 as an antitumor agent. Cancer Sci. 106:1103–1110. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kang YH, Park MY, Yoon DY, Han SR, Lee CI, Ji NY, Myung PK, Lee HG, Kim JW, Yeom YI, et al: Dysregulation of overexpressed IL-32α in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-κB and Bcl-2. Cancer Lett. 318:226–233. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nishida A, Andoh A, Inatomi O and Fujiyama Y: Interleukin-32 expression in the pancreas. J Biol Chem. 284:17868–17876. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yousif NG, Al-Amran FG, Hadi N, Lee J and Adrienne J: Expression of IL-32 modulates NF-κB and p38 MAP kinase pathways in human esophageal cancer. Cytokine. 61:223–227. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng Q, Li S, Zhou Y, Ou W, Cai X, Zhang L, Huang W, Huang L and Wang Q: Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression. Cytokine. 65:24–32. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai CY, Wang CS, Tsai MM, Chi HC, Cheng WL, Tseng YH, Chen CY, Lin CD, Wu JI, Wang LH and Lin KH: Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis. Clin Cancer Res. 20:2276–2288. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yun HM, Park KR, Kim EC, Han SB, Yoon DY and Hong JT: IL-32α suppresses colorectal cancer development via TNFR1-mediated death signaling. Oncotarget. 6:9061–9072. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Park JS, Choi SY, Lee JH, Lee M, Nam ES, Jeong AL, Lee S, Han S, Lee MS, Lim JS, et al: Interleukin-32β stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway. Cell Oncol (Dordr). 36:493–503. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Suga H, Sugaya M, Miyagaki T, Kawaguchi M, Fujita H, Asano Y, Tada Y, Kadono T and Sato S: The role of IL-32 in cutaneous T-cell lymphoma. J Invest Dermatol. 134:1428–1435. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Dahl CA, Schall RP, He HL and Cairns JS: Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol. 148:597–603. 1992.PubMed/NCBI | |
|
Kim SH, Han SY, Azam T, Yoon DY and Dinarello CA: Interleukin-32: A cytokine and inducer of TNFalpha. Immunity. 22:131–142. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kang JW, Park YS, Lee DH, Kim MS, Bak Y, Ham SY, Park SH, Kim H, Ahn JH, Hong JT and Yoon DY: Interaction network mapping among IL-32 isoforms. Biochimie. 101:248–251. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Goda C, Kanaji T, Kanaji S, Tanaka G, Arima K, Ohno S and Izuhara K: Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol. 18:233–240. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Choi JD, Bae SY, Hong JW, Azam T, Dinarello CA, Her E, Choi WS, Kim BK, Lee CK, Yoon DY, et al: Identification of the most active interleukin-32 isoform. Immunology. 126:535–542. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Heinhuis B, Koenders MI, van de Loo FA, Netea MG, van den Berg WB and Joosten LA: Inflammation-dependent secretion and splicing of IL-32{gamma} in rheumatoid arthritis. Proc Natl Acad Sci USA. 108:4962–4967. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Heinhuis B, Plantinga TS, Semango G, Küsters B, Netea MG, Dinarello CA, Smit JWA, Netea-Maier RT and Joosten LAB: Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines. Carcinogenesis. 37:197–205. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Jung MY, Son MH, Kim SH, Cho D and Kim TS: IL-32gamma induces the maturation of dendritic cells with Th1- and Th17-polarizing ability through enhanced IL-12 and IL-6 production. J Immunol. 186:6848–6859. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yun HM, Kim JA, Hwang CJ, Jin P, Baek MK, Lee JM, Hong JE, Lee SM, Han SB, Oh KW, et al: Neuroinflammatory and amyloidogenic activities of IL-32β in Alzheimer's disease. Mol Neurobiol. 52:341–352. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH and Park MH: Interleukin 32, Inflammation and Cancer. Pharmacol Ther. 174:127–137. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kang JW, Park YS, Lee DH, Kim JH, Kim MS, Bak Y, Hong J and Yoon DY: Intracellular interaction of interleukin (IL)-32α with protein kinase Cε (PKCε) and STAT3 protein augments IL-6 production in THP-1 promonocytic cells. J Biol Chem. 287:35556–35564. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Park YS, Kang JW, Lee DH, Kim MS, Bak Y, Yang Y, Lee HG, Hong J and Yoon DY: Interleukin-32α downregulates the activity of the B-cell CLL/lymphoma 6 protein by inhibiting protein kinase Cε-dependent SUMO-2 modification. Oncotarget. 5:8765–8777. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bak Y, Kang JW, Kim MS, Park YS, Kwon T, Kim S, Hong J and Yoon DY: IL-32θ downregulates CCL5 expression through its interaction with PKCδ and STAT3. Cell Signal. 26:3007–3015. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kang JW, Park YS, Lee DH, Kim MS, Bak Y, Park SH, Ham SY, Yang Y, Hong JT and Yoon DY: Interleukin-32δ interacts with IL-32β and inhibits IL-32β-mediated IL-10 production. FEBS Lett. Oct 25–2013.(Epub ahead of print). View Article : Google Scholar | |
|
Hasegawa H, Thomas HJ, Schooley K and Born TL: Native IL-32 is released from intestinal epithelial cells via a non-classical secretory pathway as a membrane-associated protein. Cytokine. 53:74–83. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Novick D, Rubinstein M, Azam T, Rabinkov A, Dinarello CA and Kim SH: Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci USA. 103:3316–3321. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Heinhuis B, Koenders MI, van den Berg WB, Netea MG, Dinarello CA and Joosten LA: Interleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1. J Biol Chem. 287:5733–5743. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Netea MG, Lewis EC, Azam T, Joosten LA, Jaekal J, Bae SY, Dinarello CA and Kim SH: Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc Natl Acad Sci USA. 105:3515–3520. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ohmatsu H, Humme D, Gonzalez J, Gulati N, Möbs M, Sterry W and Krueger JG: IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression. OncoImmunology. 6:e11812372016. View Article : Google Scholar : PubMed/NCBI | |
|
Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, Barrera P, van de Loo FA, Dinarello CA and van den Berg WB: IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA. 103:3298–3303. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P, Turato G, Lokar-Oliani K, Papi A, Zuin R, et al: IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 178:894–901. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Choi J, Bae S, Hong J, Ryoo S, Jhun H, Hong K, Yoon D, Lee S, Her E, Choi W, et al: Paradoxical effects of constitutive human IL-32{gamma} in transgenic mice during experimental colitis. Proc Natl Acad Sci USA. 107:21082–21086. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bai X, Kim SH, Azam T, McGibney MT, Huang H, Dinarello CA and Chan ED: IL-32 is a host protective cytokine against Mycobacterium tuberculosis in differentiated THP-1 human macrophages. J Immunol. 184:3830–3840. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sorrentino C and Di Carlo E: Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med. 180:769–779. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lee S, Kim JH, Kim H, Kang JW, Kim SH, Yang Y, Kim J, Park J, Park S, Hong J and Yoon DY: Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expressionof interleukin-32 controls the expression of the humanpapillomavirus oncogene. Immunology. 132:410–420. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Marcondes AM, Mhyre AJ, Stirewalt DL, Kim SH, Dinarello CA and Deeg HJ: Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci USA. 105:2865–2870. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Chen F and Tang L: IL-32 promotes breast cancer cell growth and invasiveness. Oncol Lett. 9:305–307. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lin X, Yang L, Wang G, Zi F, Yan H, Guo X, Chen J, Chen Q, Huang X, Li Y, et al: Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells. Oncotarget. 8:92841–92854. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Oh JH, Cho MC, Kim JH, Lee SY, Kim HJ, Park ES, Ban JO, Kang JW, Lee DH, Shim JH, et al: IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals. Oncogene. 30:3345–3359. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yun HM, Oh JH, Shim JH, Ban JO, Park KR, Kim JH, Lee DH, Kang JW, Park YH, Yu D, et al: Antitumor activity of IL-32β through the activation of lymphocytes, and the inactivation of NF-κB and STAT3 signals. Cell Death Dis. 4:e6402013. View Article : Google Scholar : PubMed/NCBI | |
|
Cheon S, Lee JH, Park S, Bang SI, Lee WJ, Yoon DY, Yoon SS, Kim T, Min H, Cho BJ, et al: Overexpression of IL-32alpha increases natural killer cell-mediated killing through up-regulation of Fas and UL16-binding protein 2 (ULBP2) expression in human chronic myeloid leukemia cells. J Biol Chem. 286:12049–12055. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Park ES, Yoo JM, Yoo HS, Yoon DY, Yun YP and Hong J: IL-32γ enhances TNF-α-induced cell death in colon cancer. Mol Carcinog. 53 Suppl 1:E23–E35. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Qu Y, Taylor JL, Bose A and Storkus WJ: Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32. Cancer Gene Ther. 18:663–673. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Alberti L, Bachelot T, Duc A, Biota C and Blay JY: A spliced isoform of interleukin 6 mRNA produced by renal cell carcinoma encodes for an interleukin 6 inhibitor. Cancer Res. 65:2–5. 2005.PubMed/NCBI | |
|
Sahoo A, Jung YM, Kwon HK, Yi HJ, Lee S, Chang S, Park ZY, Hwang KC and Im SH: A novel splicing variant of mouse interleukin (IL)-24 antagonizes IL-24-induced apoptosis. J Biol Chem. 283:28860–28872. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Guenin S, Mouallif M, Hubert P, Jacobs N, Krusy N, Duray A, Ennaji MM, Saussez S and Delvenne P: Interleukin-32 expression is associated with a poorer prognosis in head and neck squamous cell carcinoma. Mol Carcinog. 53:667–673. 2014.PubMed/NCBI | |
|
Lee J, Kim KE, Cheon S, Song JH, Houh Y, Kim TS, Gil M, Lee KJ, Kim S, Kim D, et al: Interleukin-32α induces migration of human melanoma cells through downregulation of E-cadherin. Oncotarget. 7:65825–65836. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Y, Hu Z, Li N and Jiang R: Interleukin-32 stimulates osteosarcoma cell invasion and motility via AKT pathway-mediated MMP-13 expression. Int J Mol Med. 35:1729–1733. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bak Y, Kwon T, Bak IS, Hong J, Yu DY and Yoon DY: IL-32θ inhibits stemness and epithelial-mesenchymal transition of cancer stem cells via the STAT3 pathway in colon cancer. Oncotarget. 7:7307–7317. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nold-Petry CA, Rudloff I, Baumer Y, Ruvo M, Marasco D, Botti P, Farkas L, Cho SX, Zepp JA, Azam T, et al: IL-32 promotes angiogenesis. J Immunol. 192:589–602. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mabilleau G and Sabokbar A: Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. PLoS One. 4:e41732009. View Article : Google Scholar : PubMed/NCBI | |
|
Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, Abraham E, Kim JM, Yoon DY, Dinarello CA and Kim SH: IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA. 102:16309–16314. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Joosten LA, Heinhuis B, Netea MG and Dinarello CA: Novel insights into the biology of interleukin-32. Cell Mol Life Sci. 70:3883–3892. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Plantinga TS, Costantini I, Heinhuis B, Huijbers A, Semango G, Kusters B, Netea MG, Hermus AR, Smit JW, Dinarello CA, et al: A promoter polymorphism in human interleukin-32 modulates its expression and influences the risk and the outcome of epithelial cell-derived thyroid carcinoma. Carcinogenesis. 34:1529–1535. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chang CJ, Chien Y, Lu KH, Chang SC, Chou YC, Huang CS, Chang CH, Chen KH, Chang YL, Tseng LM, et al: Oct4-related cytokine effects regulate tumorigenic properties of colorectal cancer cells. Biochem Biophys Res Commun. 415:245–251. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Majid S, Dar AA, Saini S, Yamamura S, Hirata H, Tanaka Y, Deng G and Dahiya R: MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer. 116:5637–5649. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zaman MS, Thamminana S, Shahryari V, Chiyomaru T, Deng G, Saini S, Majid S, Fukuhara S, Chang I, Arora S, et al: Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer. PLoS One. 7:e502032012. View Article : Google Scholar : PubMed/NCBI | |
|
Park JS, Lee S, Jeong AL, Han S, Ka HI, Lim JS, Lee MS, Yoon DY, Lee JH and Yang Y: Hypoxia-induced IL-32β increases glycolysis in breast cancer cells. Cancer Lett. 356:800–808. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zahoor M, Westhrin M, Aass KR, Moen SH, Misund K, Psonka-Antonczyk KM, Giliberto M, Buene G, Sundan A, Waage A, et al: Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss. Blood Adv. 1:2656–2666. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fukamachi T, Ikeda S, Wang X, Saito H, Tagawa M and Kobayashi H: Gene expressions for signal transduction under acidic conditions. Genes (Basel). 4:65–85. 2013. View Article : Google Scholar : PubMed/NCBI |
